Current Patent Status for Nicardipine
Nicardipine, a calcium channel blocker used for hypertension and angina, has several active US patents covering formulations, methods of use, and delivery systems. DrugPatentWatch lists 8 active patents as of the latest data, primarily held by affiliates of Chiesi Farmaceutici (e.g., for extended-release capsules like Cardene SR). These include patents expiring between 2025 and 2038, such as US 10,792,251 (expires March 2038) for controlled-release oral formulations.[1]
When Do Key Nicardipine Patents Expire?
- Earliest expirations: Patents like US 8,586,103 (Cardene SR) expired in 2021, but follow-on patents (e.g., pediatric exclusivity extensions) keep some protections alive until 2026.
- Longest protections: Newer filings like US 11,246,767 (expires 2039) cover specific hydrogel-based infusions for subarachnoid hemorrhage treatment.[1]
Full expiry timelines vary by indication; generics for immediate-release forms face fewer barriers than extended-release versions.
Who Holds the Active Patents?
Chiesi Farmaceutici and its US subsidiary (Chiesi USA) dominate, with patents assigned post-acquisition of the Cardene line from EKR Therapeutics in 2016. Earlier originator patents from Roche expired decades ago (1980s-1990s), shifting focus to secondary patents on improved delivery.[1]
Are There Ongoing Challenges or Litigation?
No major Paragraph IV challenges reported recently for nicardipine's core patents, unlike high-profile drugs. However, FDA Orange Book lists approved ANDAs for some strengths, indicating generic entry for older forms. Watch for disputes on formulation patents as 2025-2026 deadlines approach.[1]
Impact on Generics and Biosimilars
Generics exist for immediate-release nicardipine HCl (e.g., from Mylan, Apotex), but extended-release Cardene SR remains brand-protected until at least 2026 due to active patents. No biosimilars apply, as nicardipine is a small-molecule drug.[1]
[1]: DrugPatentWatch.com - Nicardipine Patents